TY - JOUR
T1 - Pretransplant solid organ malignancy and organ transplant candidacy
T2 - A consensus expert opinion statement
AU - Al-Adra, David P.
AU - Hammel, Laura
AU - Roberts, John
AU - Woodle, E. Steve
AU - Levine, Deborah
AU - Mandelbrot, Didier
AU - Verna, Elizabeth
AU - Locke, Jayme
AU - D'Cunha, Jonathan
AU - Farr, Maryjane
AU - Sawinski, Deirdre
AU - Agarwal, Piyush K.
AU - Plichta, Jennifer
AU - Pruthi, Sandhya
AU - Farr, Deborah
AU - Carvajal, Richard
AU - Walker, John
AU - Zwald, Fiona
AU - Habermann, Thomas
AU - Gertz, Morie
AU - Bierman, Philip
AU - Dizon, Don S.
AU - Langstraat, Carrie
AU - Al-Qaoud, Talal
AU - Eggener, Scott
AU - Richgels, John P.
AU - Chang, George J.
AU - Geltzeiler, Cristina
AU - Sapisochin, Gonzalo
AU - Ricciardi, Rocco
AU - Krupnick, Alexander S.
AU - Kennedy, Cassie
AU - Mohindra, Nisha
AU - Foley, David P.
AU - Watt, Kymberly D.
N1 - Publisher Copyright:
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons
PY - 2021/2
Y1 - 2021/2
N2 - Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.
AB - Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy.
KW - cancer / malignancy / neoplasia
KW - clinical research / practice
KW - editorial / personal viewpoint
KW - organ transplantation in general
KW - patient safety
KW - recipient selection
UR - http://www.scopus.com/inward/record.url?scp=85093927591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093927591&partnerID=8YFLogxK
U2 - 10.1111/ajt.16318
DO - 10.1111/ajt.16318
M3 - Review article
C2 - 32969590
AN - SCOPUS:85093927591
SN - 1600-6135
VL - 21
SP - 460
EP - 474
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 2
ER -